[1]王 震.氯氮平与氯丙嗪治疗维持期精神分裂症患者的临床疗效及安全性比较[J].医学信息,2023,36(03):152-155.[doi:10.3969/j.issn.1006-1959.2023.03.032]
　WANG Zhen.Comparison of Clinical Efficacy and Safety of Clozapine and Chlorpromazine in the Treatment of Patients with Maintenance Schizophrenia[J].Journal of Medical Information,2023,36(03):152-155.[doi:10.3969/j.issn.1006-1959.2023.03.032]
点击复制

氯氮平与氯丙嗪治疗维持期精神分裂症患者的临床疗效及安全性比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年03期
页码:
152-155
栏目:
药物与临床
出版日期:
2023-02-01

文章信息/Info

Title:
Comparison of Clinical Efficacy and Safety of Clozapine and Chlorpromazine in the Treatment of Patients with Maintenance Schizophrenia
文章编号:
1006-1959（2023）03-0152-04
作者:
王 震
（佳木斯精神病人福利院药剂科，黑龙江 佳木斯 154002）
Author(s):
WANG Zhen
(Department of Pharmaceutical,Jiamusi Psychiatric Welfare Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
精神分裂症; 氯氮平; 氯丙嗪; 阳性症状; 阴性症状; 不良反应
Keywords:
Schizophrenia; Clozapine; Chlorpromazine; Positive symptoms; Negative symptoms; Adverse reactions
分类号:
R749.3
DOI:
10.3969/j.issn.1006-1959.2023.03.032
文献标志码:
A
摘要:
目的 研究氯氮平与氯丙嗪治疗维持期精神分裂症（SP）患者的临床疗效及安全性。方法 以2019年1月-2020年2月佳木斯精神病人福利院接收的70例维持期SP患者为研究对象，采用随机数字表法进行分组，一组应用氯氮平治疗（氯氮平组），另一组采用氯丙嗪治疗（氯丙嗪组），各35例。比较两组阳性和阴性症状量表（PANSS）评分、病情康复情况[简明精神病评定量表（BPRS）、住院精神病人康复疗效评价量表（IPROS）]、临床疗效及不良反应。结果 两组治疗后PANSS评分均低于治疗前，且氯氮平组PANSS阴性量表评分低于氯丙嗪组（P＜0.05）；两组治疗后阳性量表、一般精神病理量表比较，差异无统计学意义（P＞0.05）；两组治疗后BPRS、IPROS评分均有下降（P＜0.05），但组间差异无统计学意义（P＞0.05）；两组治疗有效率比较，差异无统计学意义（P＞0.05）；氯氮平组不良反应发生率低于氯丙嗪组（P＜0.05）。结论 氯氮平与氯丙嗪治疗维持期SP疗效相当，二者均可有效改善患者阳性症状，康复效果理想，但氯氮平对阴性症状的改善作用更佳，且不良反应相对较少。
Abstract:
Objective To study the clinical efficacy and safety of clozapine and chlorpromazine in the treatment of patients with maintenance schizophrenia (SP).Methods From January 2019 to February 2020,70 SP patients in maintenance period received by Jiamusi Psychiatric Welfare Hospital were selected as the research objects. They were divided into two groups by random number table method, one group was treated with clozapine (clozapine group), the other group was treated with chlorpromazine (chlorpromazine group), with 35 cases in each group. The Positive and Negative Syndrome Scale (PANSS) scores, disease rehabilitation [Brief Psychiatric Rating Scale (BPRS), Inpatient Psychiatric Rehabilitation Outcome Scale (IPROS)], clinical efficacy and adverse reactions were compared between the two groups.Results The PANSS scores of the two groups after treatment were lower than those before treatment, and the PANSS negative scale score of the clozapine group was lower than that of the chlorpromazine group (P<0.05), while there was no significant difference in the positive scale and general psychopathological scale between the two groups after treatment (P>0.05). The BPRS and IPROS scores of the two groups decreased after treatment (P<0.05), but there was no significant difference between the two groups (P>0.05). There was no significant difference in the effective rate between the two groups (P>0.05). The incidence of adverse reactions in clozapine group was lower than that in chlorpromazine group (P<0.05).Conclusion Clozapine and chlorpromazine have similar efficacy in the treatment of SP during maintenance period. Both of them can effectively improve the positive symptoms of patients, and the rehabilitation effect is ideal. However, clozapine has a better improvement effect on negative symptoms, and has relatively few adverse reactions.

参考文献/References:

[1]Lieberman JA.Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective[J]. World Psychiatry Official Journal of the World Psychiatric Association,2018,17(2):163-165.[2]秦秋红,姜涛.盐酸丁螺环酮片联合利培酮片对稳定期精神分裂症患者阴性症状的疗效观察[J].中国医药,2018,13(6):866-869.[3]曹江,边艳辉,周佳男.氯氮平合并美金刚治疗难治性精神分裂症的疗效[J].中国慢性病预防与控制,2018,26(10):767-769[4]郗玲燕,金圭星,张素允,等.齐拉西酮联合氯丙嗪治疗老年精神分裂症患者的疗效分析[J].实用临床医药杂志,2021,25(16):116-119.[5]García-Ruiz AJ,Pérez-Costillas L,Montesinos AC,et al.Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses[J].Health Economics Review,2019,2(8):527-532.[6]张艺,郭春锋.不同抗精神病药物对精神分裂症患者心电图的影响[J].安徽医学,2018,39(2):193-195.[7]管大平.精神分裂症患者使用奥氮平或氯氮平的不良反应及其对生活质量影响[J].山西医药杂志,2018,47(12):1446-1447.[8]郑芳芳,陈士华,闻传毅,等.喹硫平与奥氮平治疗老年器质性精神障碍的疗效及对生活质量的影响[J].河北医药,201739(12):1860-1862.[9]那龙,贾晋萍.首发精神分裂症康复期综合治疗的临床研究[J].中国药物与临床,2017,17(1):110-112.[10]崔洪梅,周燕玲,李冠男,等.长期住院精神分裂症稳定期患者社会功能及影响因素[J].中国神经精神疾病杂志,2018,44(11):673-677.[11]Nikvarz N,Vahedian M,Khalili N.Chlorpromazine versus penfluridol for schizophrenia[J].Cochrane Database Syst Rev,2017,9(9):CD011831.[12]Rawal KB,Chand S,Min BL,et al.A Comparative Study on Relative Safety and Efficacy of Chlorpromazine and Risperidone in Schizophrenia patients[J].International Journal of Research in Pharmaceutical Sciences,2020,11(2):1539-1544.[13]Meyer RE.Thoughts About Schizophrenia 66 Years After Chlorpromazine[J].Journal of Clinical Psychopharmacology,2020,40(5):436-438.[14]王朔,江涛,余燕萍.氯氮平对精神分裂症患者骨密度、睾酮、泌乳素及骨质疏松的影响[J].中国现代医学杂志,2020,30(19):78-81.[15]Lin CH,Lin CH,Chang YC,et al.Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial[J].Biological Psychiatry,2017,84(6):422-432.[16]李静,袁捷,周雪丽,等.氨磺必利与氯氮平治疗阴性症状为主的精神分裂症的疗效及安全性比较[J].药物评价研究,2017,40(5):691-695.[17]王小军,张群.奥氮平与氯丙嗪对慢性精神分裂症患者近期疗效及认知功能的对比分析[J].中国药物与临床,2020,20(7):1110-1112.[18]李韧之,赵淑娟,王学升,等.氯氮平与舒必利对老年精神分裂症阳性症状疗效及安全性对照研究[J].精神医学杂志,2017,30(2):134-136.[19]Petkovic B.Novel Strategy for Electroanalytical Detection of Antipsychotic Drugs Chlorpromazine and Thioridazine; Possibilities for Simultaneous Determination[J].International Journal of Electrochemical Science,2017,12:3709-3720.[20]耿小雨,杨贵成,张景景,等.氯氮平和氯丙嗪对维持期精神分裂症认知功能与述情障碍的影响[J].国际精神病学杂志,2020,47(6):1142-1144,1147.[21]高红锐,高慧,顾燕,等.长期住院男性精神分裂症患者甲状腺激素和性激素水平及其影响因素[J].精神医学杂志,2018,31(1):19-22.[22]Rasmussen SA,Rosebush PI,Mazurek MF.The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects[J].Journal of Clinical Psychopharmacology,2017,37(1):8-12.[23]董芳,李安宁,史犇,等.氯氮平片在中国精神分裂症患者中的生物等效性研究[J].中国临床药理学杂志,2020,36(16):2486-2489.

相似文献/References:

[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
　ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Journal of Medical Information,2018,31(03):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
　ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Journal of Medical Information,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症 疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
　SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Journal of Medical Information,2018,31(03):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
　CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Journal of Medical Information,2018,31(03):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[5]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
　SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Journal of Medical Information,2018,31(03):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[6]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
　WU Jin-li.Clinical Application of Aripiprazole[J].Journal of Medical Information,2018,31(03):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
[7]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
　SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Journal of Medical Information,2018,31(03):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[8]凌 梅,刘静芳.精神分裂症患者研究伙伴的相关研究进展[J].医学信息,2018,31(19):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
　LING Mei,LIU Jing-fang.Progress in Research on Research Partners in Patients with Schizophrenia[J].Journal of Medical Information,2018,31(03):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
[9]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
　HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Journal of Medical Information,2018,31(03):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[10]陈宽玉,孔 骞,黄玉桃.首发缓解期精神分裂症患者日常生活模式的调查[J].医学信息,2019,32(04):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
　CHEN Kuan-yu,KONG Qian,HUANG Yu-tao.Investigation on the Daily Life Pattern of Patients with Schizophrenia in the First Remission Period[J].Journal of Medical Information,2019,32(03):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]

更新日期/Last Update: 1900-01-01